Antiverse Secures $9.3M Series A to Accelerate AI-Driven Antibody Discovery
UK-based biotech startup Antiverse has closed a $9.3 million Series A funding round to scale its AI-powered antibody discovery platform. The investment, led by Soulmates Ventures with participation from DOMiNO Ventures and other investors, brings the company’s total capital to over $20 million.
How Antiverse is Revolutionizing Drug Discovery with AI
Antiverse specializes in targeting “undruggable” disease mechanisms like G-protein coupled receptors (GPCRs) and ion channels—molecular targets responsible for 80% of diseases but historically resistant to traditional drug development. Their AI platform designs therapeutic antibodies that bind to these complex targets, with lab validation systems replicating human biology to test candidates.
Key Innovations
- Machine learning models generate antibodies for specific disease targets
- Proprietary cell systems validate antibody effectiveness in human-like conditions
- Collaboration with Cystic Fibrosis Foundation to target the CFTR protein
Why This Matters for Modern Medicine
With 90% attrition rates in clinical trials for complex targets, Antiverse’s approach could dramatically reduce development costs and timelines. The company’s platform enables rapid iteration between computational design and experimental validation, accelerating the path from discovery to clinical testing.
Funding Applications
The Series A will:
- Scale the AI antibody platform for pharmaceutical partners
- Expand internal drug development pipelines
- Advance lead candidates toward in vivo efficacy studies
What This Means for Patients
By focusing on targets linked to cancer, neurological disorders, and rare diseases like cystic fibrosis, Antiverse’s technology could unlock treatments for conditions previously considered untreatable. The partnership with the Cystic Fibrosis Foundation highlights the platform’s potential to address historically challenging proteins.
Conclusion: The Future of Biotech Meets AI
Antiverse’s $9.3M Series A marks a significant step forward in AI-driven drug discovery. As the company scales its platform, it could redefine how we approach complex diseases. Stay tuned for updates on this groundbreaking technology.
FAQs
- What is Antiverse’s AI antibody platform?
- A machine learning system that designs therapeutic antibodies for undruggable disease targets.
- How does AI improve antibody discovery?
- AI enables faster design iterations and more accurate predictions of antibody effectiveness.
- What diseases is Antiverse targeting?
- Cancer, neurological disorders, and rare diseases like cystic fibrosis.
- Who are Antiverse’s investors?
- Soulmates Ventures, DOMiNO Ventures, and existing investors including DBW and Kadmos Capital.
- What’s next for Antiverse?
- Advancing lead candidates toward in vivo studies and expanding pharmaceutical partnerships.
